You have read all your free articles, to continue reading subscribe to read the rest of this content.
Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and aAlready a subscriber Login You have read all your free articles,…
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the first child dosed, this Phase 3 trial takes an important step toward establishing dasiglucagon as a potential treatmenAlready a subscriber…
Ilya Pharma has completed recruitment for a Phase I trial of its lead candidate ILP100-Topical. Progress has been rapid considering ILP100 is the first drug based on genetically engineered Lactobacillus to be approved to enter trials which has necessitated innovations in CMC, bioassays and protocAlready a subscriber Login You have…
IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s disease (PD-LIDs). The top-line results are expected to be reported in mid-January 2023, Already a subscriber Login You have read…
